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Abstract. When the human erythroleukemia cell line 
K562 is treated with OKT9, a monoclonal antibody 
against the transferrin receptor, effects on receptor dy- 
namics and degradation ensue. The apparent half-life 
of the receptor is decreased by >50% as a result of 
OKT9 treatment. The transferrin receptor is also rap- 
idly redistributed in response to OKT9 such that a 
lower percentage of the cellular receptors are displayed 
on the cell surface. OKT9 treatment also leads to a 
decrease in the total number of receptors participating 
in the transferrin cycle for cellular iron uptake. The 
reduction in iron uptake that results from the loss of 
receptors from the cycle leads to enhanced biosyn- 
thesis of the receptor. Receptors with bound OKT9 
continue to participate in multiple cycles of iron up- 
take. However, OKT9 treatment appears to result in a 
relatively small increase per cycle in the departure of 
receptors from participation in iron uptake to a path- 
way leading to receptor degradation. Radiolabeled 
OKT9 is itself  degraded by K562 cells and this degra- 
dation is inhibitable by leupeptin or chloroquine. In 
the presence of leupeptin, OKT9 treatment results in 
the enhanced intracellular accumulation of transfer- 
fin. Because the time involved in the transferrin cycle 
is shorter 02.5 min) than the normal half-life of the 
receptor (8 h), a small change in recycling efficiency 
caused by OKT9 treatment could account for the 
marked decrease in receptor half-life. In this paper the 
implications of these findings are discussed as they 
relate to systems in which receptor number is regu- 
lated by ligand. 
p 
ROLIFERATING cells require  exogenous iron  and ac- 
quire it via receptor-mediated endocytosis of the iron- 
carrier protein transferrin (Tf)  1  (for review see reference 
6). Iron uptake via the Tf cycle involves binding of diferric 
Tf to a  specific, high-affinity surface receptor  followed by 
internalization  of the receptor  ligand complex. Within the 
cell, the complex encounters an acidic (~pH 5) environment 
that is instrumental in iron unloading (22, 31). Apo-Tf is then 
released intact  from  the  cell, and the transferrin  receptors 
(TtR) are reused (2, 9). The Tf cycle shares certain aspects 
with other systems of receptor-mediated endocytosis but also 
exhibits distinctive features, including the return  of unde- 
graded ligand and receptor to the cell exterior. 
In the present study, we describe perturbations of  the path- 
way traversed by the TfR that result from exposure of K562 
cells to a  monoclonal  anti-receptor  antibody (OKT9). The 
monoclonal antibody OKT9 recognizes the human TfR at a 
site distinct from the ligand binding site and has been used to 
examine the structural features of the receptor as well as in 
the chromosomal localization and cloning of the TfR gene 
(3, 15, 25). We have found that treatment of K562 cells with 
OKT9 affects receptor distribution and the rates of receptor 
f Abbreviations used in this paper." Tf, transferrin; TfR, Tf receptor. 
degradation and biosynthesis. Many of the effects of OKT9 
on TfR dynamics in  K562 cells resemble phenomena ob- 
served in other endocytic systems including what is thought 
to be physiologic modulation of receptor function. Accord- 
ingiy, we believe that certain implications of our experiments 
may be generally applicable to receptor dynamics. 
Materials and Methods 
Cells and Chemicals 
K562, a human erythroleukemia  cell line, was grown in RPMI  1640 with 25 
mM Hepes containing  10%  fetal bovine serum, penicillin, and streptomycin 
(growth medium). Ceils were maintained  at densities of 2-6 ×  105/ml at 37"C 
in 5% CO2 incubator. 
Human Tf (Calbiochem-Behring Corp., San Diego, CA) was made diferric 
by  published  procedures  (1 I).  Anti-TfR  monoclonal  antibody  OKT9  was 
prepared from ascities fluid using DEAE Affigel blue (Bio-Rad Laboratories, 
Richmond,  CA) as previously described (1). It was further purified by high- 
pressure liquid chromatography by passage through a TSK G3000 SW column 
(LKB  Instruments,  Gaithersburg,  MD)  with  elution  in  phosphate-buffered 
saline (PBS) at 0.5 ml/min. 0.25-ml fractions were collected and the IgG peak 
was detected  by  absorbance  at  280  nm.  Monoclonal  antibody  B3/25  was 
obtained from Boehringer-Mannheim Diagnostics (Houston, TX) and exhaus- 
tively dialyzed against PBS. 
Tf and IgG were iodinated by Enzymobeads (Bio-Rad Laboratories) accord- 
ing to the supplier's  instructions.  After from 30 min to  1 h of iodination  at 
room temperature  the reaction  mixture was passed through a Sephadex G-25 
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mM Tris-HCl, pH 7.4 (for TO, or PBS (for OKT9), and the protein peak was 
recovered. Specific activities ranged from  240  to 2,400 cpm/ng protein,  de- 
pending on the nature and amount of protein  iodinated. Tf radiolabeled with 
~gFe was prepared by methods previously published (11). 
Hemin (ferric protoporphyrin IX) was purchased from Porphyrin Products, 
Inc. (Logan, UT).  Just before use, hemin was dissolved in 0.2  M Na2CO3/ 
NaHCO2, pH 10.7, and the pH was adjusted to 7.4 with 1 M HCI. This solution 
was filtered through a 0.45-~m filter before addition to cells. 
Degradation 
Rates  of degradation  of the  TfR  were assessed using metabolically  labeled 
receptor. Metabolic labeling was achieved by incubating  K562 cells (5 x  105/ 
ml) in  methionine-free  RPMI  1640 medium containing  10%  dialyzed  fetal 
bovine  serum and  50  #Ci/ml  [aSS]methionine (1,000 Ci/mmol, Amersham 
Corp., Arlington Heights, IL). After 2 h in a 37"C incubator, cells were washed 
three times with K562 growth medium and returned to the incubator. Receptor 
degradation  experiments  were begun 45  rain later, when the  cell suspension 
was divided and the desired additions were made. Immediately and at intervals 
thereafter,  samples were removed,  and the  content  of radiolabeled  TfR was 
determined  by cell lysis, immunoprecipitation,  gel electrophoresis, and auto- 
radiography. At each time point, cells were pelleted and lysed in  1 ml ice-cold 
1%  Triton  X-100, 0.5% sodium  desoxycholate, 0.15 M NaCI, 0.01 M Tris- 
HCI. pH 7.4, 0.1% bovine serum albumin ([BSA] lysis buffer). Immediately, 
the solubilized cells were made 0.1  mM in phenylmethylsulfonyl fluoride, 0.5 
trypsin inhibitor  units (TIU)/ml in aprotinin  (Sigma Chemical Co., St. Louis, 
MO) and  10 #g/ml in leupeptin (Boehringer Mannheim Diagnostics). After 30 
min on ice, the samples were centrifuged at  13,000 g for 10 min. The super- 
natant  fluid was removed  and stored  at  -70"C until  all time point samples 
were collected. 
Immunoprecipitation  was accomplished  using  an  IgG fraction  prepared 
from the plasma of  a goat injected with TfR purified from K562 cells by affinity 
chromatography on Tf-Sepharose. In preliminary experiments it was established 
that the presence of OKT9 did not affect immunoprecipitation  of the human 
TfR by the goat IgG (data not shown). In some experiments, 25 #g goat anti- 
receptor IgG was added to 0.5 ml cell lysate supernatant fluid whereas in others 
50 #1 of Sepharose CL6B (Pharmacia  Fine Chemicals) containing  50 ug cova- 
lently bound goat anti-receptor  IgG were added. In the former case, precipita- 
tion  was  achieved  using  protein  A-Sepharose (Pharmacia  Fine  Chemicals) 
coated  with rabbit anti-goat IgG (Cappel Laboratories, Cochranville,  PA). In 
both cases, the resins were tumbled for 90 min at 4"C before being centrifuged 
and washed three times with 1 ml lysis buffer lacking serum albumin. The resin 
pellets were then heated  for 5 min at 95"C in electrophoresis sample buffer. 
The released proteins were electrophoresed on 12.5% polyacrylamide gels cross- 
linked with Acrylaide and bonded to Gel Bond (FMC Corp., Chicago, IL) using 
the buffer system of Laemmli (16). After fixation, gels were impregnated with 
1 M sodium  salicylate and dried in a 60"C oven. Dried gels were exposed to 
Kodak XAR 5 film at 70"C. The amount of radiolabeled TtR present in each 
sample  was quantitated  from the  resultant  autoradiograph  using a  Hoefer 
scanning densitometer (Hoefer Scientific Instruments, San Francisco, CA) and 
peak integration. 
Biosynthesis 
The rate of biosynthesis of the TfR was also assessed by immunoprecipitation, 
gel electrophoresis,  and autoradiography.  In these biosynthetic  experiments, 
K562 cells (1  x  106/ml) were incubated  for 30 min in RPMI  1640 medium 
containing  one-tenth  the  normal amount of methionine,  10%  fetal bovine 
serum, and 0.2 mCi/ml [aSS]methionine.  Analyses of  the radiolabeled cells were 
accomplished essentially as described above except that OKT9 IgG (5 #g) and 
Protein  A-Sepharose (Pharmacia  Fine Chemicals) were used for immunopre- 
cipitation. The treatments  shown to affect TfR biosynthesis did not alter [3~S]- 
methionine  incorporation  into total cellular protein as judged by 10% trichlo- 
roacetic acid precipitation of radioactivity. 
Soluble Receptor Assay 
K562 cells (1.2 ×  l&) were solubilized in 0.5 ml ice-cold 0.5% Triton  X-100, 
0.15 M NaCI, 10 mM Tris-HCl, pH 7.4, 0.1 mM phenylmethylsulfonyl fluoride, 
0.5  TIU/ml Aprotinin,  2.5  tag/ml ~251-Tf. After 45  min on ice, 0.5  ml 60% 
saturated ammonium sulfate (adjusted to pH 7.6 with "Iris base) was added, 
and this mixture was incubated  for 15 min at room temperature.  The ammo- 
nium sulfate-precipitated  receptor-ligand complex was recovered by filtration 
on a Whatman GF/C filter (Whatman Laboratory Products Inc., Clifton, N  J) 
which was subsequently  washed twice with  3 ml 30%  saturated  ammonium 
sulfate. Nonspecific binding was assessed by inclusion of 250 ug of unlabeled 
human diferric Tf in the solubilization mixture. The presence of  OKT9 did not 
affect the values obtained using this soluble receptor assay (data not shown). 
Binding and Uptake Studies 
Binding studies with either '25I-Tf  or '25I-OKT9  were carried out in RPM!  1640 
with 25  mM Hepes, pH 7.4, containing  0.1% BSA (assay medium).  Binding 
experiments  were performed  at  12~l-Tf concentrations  of -> 10 #g/ml.  Under 
these conditions  no effect of the presence of OKT9 on the amount of ~25I-Tf 
bound was seen. Nonspecific binding was determined by the addition of a 100- 
fold excess of the  unlabeled material of interest. Cell-associated radioactivity 
was separated from unbound material  by layering of 200 ~1 cell suspension 
over  150  gl  of either  1 M  sucrose  in  PBS, pH  7.2-7.4,  or  150  t~l  dibutyl 
phthalate  (Aldrich Chemical Co., Milwaukee, Wl) in 400-~1 microfuge tubes 
(Bio-Rad Laboratories). The cells were pelleted by centrifugation in a Beckman 
microfuge (Beckman  Instruments Inc.,  Palo Alto,  CA) for  1 min.  The  tips 
containing  cell pellets were cut and their content  of '25I was determined  in a 
Packard  Auto Gamma 5060 gamma-counter  (Packard  Instrument Co., Inc., 
Downers Grove, IL). In untreated cells, the nonspecific binding/uptake  always 
represented <15%  of total cell-associated radioactivity and was usually -5%. 
The  absolute  levels of  nonspecific  binding/uptake  were  not  significantly 
changed by any of the treatments employed. 
Results 
Effect of  Anti-receptor  Antibody on the 
Degradation of the TfR 
Treatment ofK562 cells with mouse monoclonal IgG (OKT9) 
against the TfR resulted in a decrease in the apparent half-life 
of the TfR from ~8 to ~4 h. This effect of OKT9 on receptor 
degradation  was  assessed by  pulse-chase  experiments  using 
cells labeled metabolically with [35S]methionine (Fig.  1) or in 
chase  experiments  after  surface  radioiodination  (data  not 
shown).  The  apparent  half-life  of total  cellular  proteins  in 
K562 cells as judged by the loss of 10% trichloroacetic acid- 
precipitable radioactivity was found to be ~ 19 h. The presence 
of saturating levels of human Tf did not affect the degradation 
rate  of the  TfR  (18),  nor  did  added  human  Tf  alter  the 
enhanced degradation  rate seen in OKT9-treated  cells.  An- 
other monoclonal antibody against the human TfR (B3/25) 
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Figure 1. Effect of OKT9 treatment on the degradation of the TfR. 
K562 cells were metabolically labeled with [3SS]methionine for 2 h at 
37"C as described in Materials and Methods. After being washed free 
of unincorporated [35S]methionine and incubated for an additional 
45-min at 37"C,  the cell suspension was divided,  and OKT9 (5 #g/ 
ml) was added to half of the cells.  At the indicated times thereafter, 
samples were removed and their content of radiolabeled receptor was 
determined by immunoprecipitation, gel electrophoresis, autoradiog- 
raphy,  and  densitometry  as  described  in  Materials  and  Methods. 
Values are expressed as percentages of the value obtained at the time 
of antibody  addition.  Shown  are  the  first-order decay  curves  for 
untreated (0) and OKT9 treated (©) cells. 
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dation  whereas an  unrelated  monoclonal antibody (OKT3) 
did not.  To determine whether receptor shedding might ac- 
count for the OKT9  effect, we solubilized and immunopre- 
cipitated K562  cells together with their incubation medium 
rather than  the  washed  cells alone. Here,  a  similar OKT9- 
mediated decrease in receptor half-life was observed, arguing 
against a shedding of TfR in response to OKT9 treatment as 
an explanation of the OKT9 effect. When the OKT9 IgG was 
itself radioiodinated and incubated with K562  cells at 37"C, 
the  ~z~I-IgG became  associated with  the  cells at  at  a  level 
approximately twofold higher than  the  binding capacity of 
the cell surface (Fig. 2). Between 2 and 3  h  of incubation the 
leveI of cell-associated ~'-~I-IgG began  to decline. All of the 
loss of cell-associated radioactivity could be accounted for in 
10% tricbloroacetic acid-soluble radioactivity, suggesting that 
proteolysis occurred. The loss of radioactivity from the cells 
and appearance of acid soluble radioactivity were prevented 
by  inclusion  of the  protease  inhibitor  leupeptin.  In  other 
experiments, we found that chloroquine also inhibited  ~25I- 
OKT9 degradation (data not shown). 
Effect of  Anti-receptor Antibody on the Cellular 
Content and Biosynthesis of the TJR 
The  antibody-mediated increase in  TfR  degradation would 
be expected ~o result ir~ a corresponding decrease ~n the steady 
state content  of cellular TfR.  However,  when  TfR binding 
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Figure 3  Effect of OKT9 treatment on cellular content of transferrin 
receptors.  OKT9 (2 ug/ml) was added to K562 gro,,cth cultures such 
that the indicated treatment times were attained. The ceLis  (2 ×  i06) 
were centrifuged,  lysed in detergent, and the ~2~I-Tf  binding capacity 
of the solubilized cells was determined as described in Materials and 
Methods.  Values are expressed as percentages  of the value obtained 
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Figure 2.  Uptake  and  degradation  of 125I-OKT9.  K562  cells  were 
washed into ice-cold assay medium. To the suspension of cells ( 1 × 
106 cells/ml), 1 ~g/ml 125I-OKT9 was added and the cell suspension 
was incubated at 4"C for 30 min before rewarming.  Leupeptin (0.1 
mg/ml) was added to these incubations where indicated (0, II). Cells 
were warmed to 37"C in a 5% C02 incubator for the indicated times 
when  samples were  rer,  c~ved and call-associated ~z~I-OKT9 (11, O) 
was determined as described in Materials and Methods, To determine 
the extent of degradation of ~2sI-OKT9 samples of the cell suspension 
were added to an equal volume of ice-cold 20% trichloroacetic acid, 
4%  phosphotungstic acid. After 30  rain  on  ice, this material was 
centrifuged and the amount of acid-soluble radioactivity was deter- 
mined (11, I-3).  For the cultures not receiving  leupeptin, cell-associated 
and acid-soluble  radioactivity  have been summed (A) to demonstrate 
that  all radioactivity lost from  the cells can  be  accounted  for as 
degraded ~25I-OKT9. To account for acid-soluble radioactivity that 
was  not clue to  cellular uptake,  flasks containing the appropriate 
media and ~25I-OKT9 were incubated wilhout K562  cells, and cor- 
responding values were subtracted, 
Figure 4  EffecI of various treatments on role of biosynthesis of the 
TfR  K562  cells were incubated for 6 h at 37"C with  no additions 
(}aBe A), 5 #g/mi OKT9 (lane B), 5 ~g/ml B3/25 (lane C), 40 ~g/ml 
human diferric Tf(lane D), or 5 t~g/ml OKT9 plus 40 ug/ml human 
diferric Tf (lane E).  Cells (1  x  10  ~)  from  each  incubation  were 
centnfuged, and the rate of receptor biosynthesis was determined by 
pulse-labeling with  3SS-methionine,  immunoprecipitation, electro- 
phoresis, and autoradiography  as described in Materials  and Methods. 
The upper portion of the figure displays the results  of quantitative 
densitometry of the  autoradiograph. These  data are expressed  as 
percentages of the value obtained for control cells (lane A). 
sites were measured in detergent-solubilized  cells after lengthy 
treatment  with  OKT9,  the  level  of TfR  was  found  to  be 
decreased  by  <30%  (Fig.  3)  despite  a  ~50%  decrease  in 
receptor survival time.  The relatively smaller drop in  total 
receptor number led us to assess directly the biosynthetic rate 
of the  receptor in OKT9-treated cells. The  results shown in 
Fig. 4  demonstrate that treatment with OKT9  resulted in a 
greater than twofold increase in the rate of TfR biosynthesis. 
In contrast, cells treated with saturating levels of human  Tf 
exhibited a  rate of biosynthesis that is decreased to <50%  of 
the control value. This human Tf effect has been previously 
documented  by  our  laboratory and  appears  to  be  due  to 
decreased levels of TfR mRNA resulting from transcriptional 
modulation (18, 20, 21). A decrease in receptor biosynthesis 
was also seen when cells were treated with other iron-supply- 
953  Weissman  et al. Effect of  Antibody OKT9 on K562 Cells ing substances such as ferric ammonium citrate (21) or hemin 
(24).  Simultaneous  treatment  with  human  diferric  Tf and  "- 
x 
OKT9  (Fig.  4)  has  the  effect of preventing the  enhanced  li 
biosynthesis of TfR seen in  cells treated with OKT9 alone. 
To evaluate whether the biosynthetic effect of OKT9 might  .l~ 
be related to iron  deprivation,  hemin  was employed as an 
iron source. We have recently shown that hemin can serve as 
a very efficient source of chelatable iron that can depress TfR 
biosynthesis. In the presence of hemin, OKT9-mediated re-  _ 
duction of  total cellular TfR is considerably more pronounced 
(Table I), owing to lower rates of receptor biosynthesis under 
these conditions. These results, suggest that the OKT9 effect  "~ 
on TfR biosynthesis is probably a  secondary effect resulting 
a} 
from a decrease in iron within the regulatory iron pool. 
Effect of  Anti-receptor Antibody on the Tf  Cycle 
The effect of antibody on a  single  Tf cycle was examined. 
After  '~I-Tf was  prebound  to  the  cell  surface  at  4"C  and 
unbound  ~2~I-Tf  was removed, cells were warmed to  37"C 
(Fig.  5). There was no detectable effect of OKT9 treatment 
Table I. Effect of OKT9 and/or Hemin on the Number of 
Cellular TfR 
Treatment  '2SI-Tf  Bound  % of  control 
cpm 
None  37,400  100 
OKT9  26,462  70.7 
Hemin  35,676  95.7 
OKT9 + Hemin  18,588  49.7 
K562 cells were treated as indicated with OKT9 (2 ~g/ml), hemin (50 uM), or 
OKT9 plus hemin. After 6 h at 37"C in a 5% CO2 incubator, 1.4 x  106 cells 
were subjected to the soluble TfR assay described in Materials and Methods. 
Values shown represent the average of duplicate determinations. 
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Figure 5. Effect of OKT9 treatment on efflux of cellular transferrin. 
K562 cells were cooled to 4"C, centrifuged, and resuspended at 3.5 x 
106/ml in ass~ medium. After the addition of 1.25 ~tg/ml OKT9 (O) 
or no addition (O), the cell suspensions were warmed to 37"C for 45 
min. After cooling to 4°C, 5 #g/ml of J25I-Tfwas added, and the cell 
suspension was incubated at 4"C for 15 rain. The cells were washed 
twice at 4°C  to remove unbound ligand and resuspended in assay 
medium containing 5 ug/ml unlabeled human diferric Tf to prevent 
rebinding of radiolabel. OKT9 (1.25 gg/ml) was restored to those cell 
suspensions  that had been pretreated with the antibody. The suspen- 
sions were warmed to 37°C, and, at the indicated times, samples (0.2 
ml) were removed and cell-associated radioactivity was assessed as 
described in Materials and Methods. Values are expressed as percent- 
ages of the initial value, and standard errors are shown. The inset 
provides a semilogarithmic plot of  data showing that single exponen- 
tial functions define the loss of cell-associated ~25I-Tf  in both control 
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Figure 6. The influence of OKT9 and leupeptin on the retention of 
cellular  '2~I-Tf. K562  cells were cooled  to  4"C,  centrifuged, and 
resuspended at 4"C at 5 x  106/ml in in assay medium in the presence 
of leupeptin (0.1 mg/ml). Suspensions then were made 20 ug/ml in 
~25I-Tfand warmed to 37"C. After 15 min of warming, either OKT9 
(1  #g/ml) (@) or an equivalent volume of PBS (©) was added. The 
cell  suspensions were kept at 37"C  for an additional 75  min. Cells 
were then cooled to 4"C and washed twice in ice-cold assay medium 
before being resuspended at 5 x  106/mi in assay medium containing 
80  ug/ml  unlabeled human diferric Tf and  0.1  mg/ml leupepfin. 
OKT9  was included in  the washes and  resuspension medium  as 
indicated above. The cell suspensions were then once again warmed 
to 37"C for the indicated times when samples (0.2 ml) were removed 
and cell-associated  radioactivity was assessed  as described  in Materials 
and Methods. All measurements were performed in quadruplicate, 
and the values obtained varied from the mean no more than -+5%. 
on the lag time (-4 min), rate (ll/2 =  5 min), or extent (~98%) 
of the exponential loss of cell-associated ligand. 
Because the TfR participates in many cycles of iron uptake 
in its lifetime, a relatively small increase in the percentage of 
the TfR being degraded per cycle could be responsible for the 
enhanced  receptor degradation seen in  OKT9 treated cells. 
Since Tf does not dissociate from TfR in the Tf cycle (2, 6, 
9) OKT9 might also be expected lead to intracellular accu- 
mulation of J25I-Tf.  Ifa small percentage of the receptor ligand 
complexes engaged in each Tf cycle were to leave the cycle 
and remain within the cell pending degradation, this would 
be detected  only if ligand  molecules that had departed the 
cycle were allowed to accumulate over multiple cycles.  An 
experiment of this nature is shown in Fig. 6. In OKT9-treated 
cells  -15 % of the radiolabeled ligand that had accumulated 
in a  90-min incubation with  125I-Tf  was retained within the 
cell during the second 90-min incubation with excess unla- 
beled ligand in the medium. In control cells <7% of the '25I- 
Tf was found in this nonexchangeable pool. This experiment 
was performed in the presence of the protease inhibitor leu- 
peptin to prevent proteolytic breakdown of the  ~25I-Tf. The 
levels on nonexchangeable ligand in both control and OKT9- 
treated cells were significantly decreased by omission of leu- 
peptin (data not shown). These results together with those in 
Fig. 2 suggest that OKT9 enhances movement of the antibody 
receptor-ligand  complex  from  the  normal  Tf cycle  to  an 
intracellular  pathway that  terminates in  leupeptin-sensitive 
degradation  of receptor-associated OKT9  and  of receptor- 
associated ligand. 
When  K562 cells  are incubated at  37"C  with  ~25I-Tf, the 
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represents the steady state between endocytosis of diferric Tf 
and exocytosis of apo Tf (2,  9). In the course of the normal 
Tf cycle, this  provides an  estimate  of the  number of TfR 
involved in iron delivery, i.e., this level of cell-associated '2~I- 
Tf serves as a measure of the cycling pool of TfR. Treatment 
of cells with OKT9 results in a decrease in the apparent size 
of this cycling pool (Fig. 7). Consistent with the results in Fig. 
5, the rate at which the cycling pool is filled with ligand does 
not appear to be markedly affected by treatment with OKT9. 
The  results presented  above demonstrate that  most cell- 
associated Tf is released when OKT9 is present (Figs.  5 and 
6) but that, after treatment with OKT9, cells increase their 
accumulation of  Tfduring multiple cycles (Fig. 6). To confirm 
that continued uptake of iron via the Tf cycle is occurring in 
the presence of Tf and OKT9, uptake of ~gFe from [S9Fe]Tf 
was compared in control and OKT9-treated cells (Fig. 8). The 
uptake rate (slope) in OKT9-treated cells was decreased ~20% 
as compared with that seen in the control cells. These results 
demonstrate that the  Tf cycle is operative in OKT9-treated 
cells and that iron  uptake is decreased commensurate with 
the reduction shown in Fig.  7 of the number of TfR within 
the cycling pool. These results do not rule out the possibility 
that continued iron uptake in the presence of OKT9 is due 
to entry of new receptors into the system. The inset of Fig. 8 
argues against this possibility. Here cells were incubated in 
the  presence  of  '2sI-OKT9  under  conditions  used  in  SgFe 
uptake experiments. As receptor-bound OKT9 does not read- 
ily dissociate from K562 cell membranes at 37°C (data not 
shown),  this  inset  can  be  interpreted  to  indicate  that  no 
significant number of receptors without bound OKT9 appears 
at the cell surface in the period (2-3 h  of OKT9 treatment) 
during which S9Fe uptake was measured. Thus, it appears that 
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Figure 7. Effect of OKT9 treatment on the cycling pool of TfR. K562 
cells were treated with 2 ttg/ml OKT9 for  1 h at 37"C in a  5% CO2 
incubator. The cells were then centrifuged and resuspended in assay 
medium at 5.5 x  106/mi. The cell suspension were warmed to 37"C 
and added to an equal volume of prewarmed assay medium contain- 
ing 20 ~tg/ml  '2~l-Tf.  Duplicate samples (0.2  ml) were taken at the 
indicated times and the cell-associated radioactivity was assessed as 
described in Materials and Methods. Cell-associated radioactivity for 
OKT9-treated (O) and for untreated (e) cells is shown. The plateau 
value represeming the steady state between diferric Tf uptake and 
apo-Tf release has been taken as a  measure of the number of TfR 
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Figure 8.  Effect of OKT9 treatment on iron uptake in K562  cells. 
K562 cells were treated where indicated (e) with 1 ug/ml OKT9 for 
2 h  at 37"C in a  5% CO2 incubator. Cells were then cooled to 4"C, 
centrifuged, and resuspended at 2.8 x  106/ml in ice-cold assay me- 
dium. OKT9 (1 ttg/ml) was re-added to the appropriate cell suspen- 
sions. ~gFe-Tf 9,000 cpm/~tg) was then added at a  concentration of 
40 ttg/ml, and after 20 min at 4"C the cells were warmed to 37"C. At 
the indicated times cell-associated 59Fe was assessed as described in 
Materials and Methods. A comparison was made to cells not treated 
with OKT9 (O). Standard errors are shown. In the inset is shown cell- 
associated  '25I-OKT9 in a  parallel experiment in which K562 cells 
were incubated at  37"C with  1 ttg/ml  '25I-OKT9.  At the indicated 
times cells were cooled to 4"C, centrifuged, and resuspended in assay 
medium at 4  x  106/ml. Cell-associated radioactivity was assessed as 
described in Materials and Methods. The zero-time value represents 
the value for cell-associated '2~I-OKT9 obtained with unwarmed cells. 
most of the receptors with bound OKT9 continue to partici- 
pate in the Tf cycle and continue to mediate iron uptake. 
Effect of  Anti-receptor Antibody on the 
Distribution of the TfR 
It is clear from the above data that both cycling pool receptors 
and total cellular receptors are reduced by OKT9 treatment. 
Accordingly, we addressed the question of whether this reduc- 
tion  was  proportionally reflected  in  both  cell  surface  and 
intracellular receptors (Fig.  9).  Receptors disappeared from 
the cell surface (Fig. 9A) at a rate exceeding reduction in the 
cycling pool (Fig. 9 B). In the inset of Fig. 9 B, it can be seen 
that the reduction in the number of cell surface receptors can 
be described by two exponential functions, the slower of  which 
resembles the rate of reduction in the size of the cycling pool. 
The effect of the initial rapid component is a  redistribution 
of the cycling pool with the result being less representation 
on the cell surface. In a number of experiments, we observed 
that OKT9 induced a 40-60% decrease in the fraction of the 
cycling pool receptors that are displayed on the cell surface. 
Discussion 
Receptor-mediated endocytosis provides the means for inter- 
nalization of ligands and receptors in many systems (19,  26). 
The events that follow internalization and the ultimate fate 
of the ligand and receptor molecules are qualitatively different 
in  various endocytic  systems.  In  certain  cases,  ligands  are 
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Figure  9.  Effect  of OKT9  treatment  on  surface  and  cycling  pool 
receptor numbers. K562 cells (4 x  105/ml) were treated with 1 ~g/ 
ml OKT9 (0) for the indicated times in a 5% CO2 incubator at 37"C. 
Control cells (O) received an equivalent volume of PBS. For zero 
time points, cells were cooled before the addition. The additions were 
staggered so that all cells were removed from incubation at the same 
time. The cells were then cooled to 4°C, centrifuged, and resuspended 
at 4 x  10~/ml in assay medium containing ~ZSl-Tf  (20 ~g/ml). OKT9- 
treated cells had antibody re-added. Surface receptors (A) were deter- 
mined by maintaining cells at 4"C for 45 min before assessment of 
cell-associated radioactivity as described in Materials and Methods. 
Cycling pool receptors (B) were determined by warming cells for 45 
rain to 37"C and then cooling to 4"C to measure total cell associated 
radioactivity. The B inset shows surface (11) and  cycling pool (A) 
receptor numbers for OKT9-treated cells plotted semilogarithmically. 
The ratio of  the values obtained for surface and cycling  pool receptors 
is plotted in C for control (O) and OKT9 treated (O) cells. Standard 
errors are shown. 
degraded and their receptors reused whereas, in others, both 
ligand and receptor are destroyed. During Tf-mediated iron 
uptake,  both  undegraded  Tf molecules and  TfR  are  over- 
whelmingly returned to the cell exterior (6). There is compel- 
ling evidence from many endocytic systems that the degree of 
recycling of receptor and ligand is well regulated. There exist 
multiple possible mechanisms by which  receptor functions 
might be modulated. Alteration of the location of receptors 
within the cell may render them more or less available without 
changing the total cellular content of receptor molecules. The 
actual number of receptors can be altered by changes in rates 
of biosynthesis and/or  degradation.  Alternatively,  function 
may be directly modulated either by changes in the affinity 
of the receptor for ligand or through effects on the transduc- 
tion of signals that arise from ligand binding. 
Treatment of K562 cells with OKT9 results in two major 
effects related to receptor dynamics. Such treatment leads to 
an ~50% reduction in the apparent half-life of the TfR and 
the receptors engaged in iron  uptake are redistributed.  The 
enhancement of receptor degradation leads to a reduction in 
the steady state cellular content of TfR by ~30%. However, 
this reduction in TfR content is not as pronounced as would 
be expected based upon the magnitude of the effect on recep- 
tor half-life.  This apparent discrepancy is reconciled by the 
finding that OKT9 treatment also leads to an approximate 
doubling of the rate of TtR biosynthesis. This effect of anti- 
receptor antibody on receptor biosynthesis is probably medi- 
ated via an intracellular regulatory pool of iron. Iron supplied 
by human  diferric  Tf through  the  TfR or by hemin  via a 
pathway not involving the TfR was shown to result in sup- 
pression of the OKT9 effect on TfR biosynthesis. The mech- 
anism by which OKT9 treatment leads to enhanced receptor 
degradation remains obscure. It is possible that receptor cross- 
linking  by  divalent  IgG  at  some  point  in  the  process  is 
involved. Receptor cross-linking has been implicated in  en- 
docytosis mediated by the  IgG Fc receptor (19).  However, 
note that ligands (e.g., insulin, epidermal growth factor) not 
thought  to  be  capable of direct  receptor cross-linking can 
nonetheless mediate receptor down regulation. 
Treatment with OKT9 results in a reduction in the number 
of TfR that  are  participating  in  iron  uptake.  This  loss  of 
receptors  from  the  cycling  pool  leads  to  a  corresponding 
decrease in SgFe accumulation from [SgFe]Tf. Trowbridge and 
Domingo (29) have reported that the antibody B3/25  (that 
like OKT9 does not block Tf binding to the TfR) can inhibit 
human tumor cell growth in nude mice. One possibility raised 
by these authors was that B3/25 might interfere in some way 
with  tumor cell  iron  uptake.  Our results with OKT9 agree 
with this hypothesis. 
Although OKT9 leads to a decrease in the number of total 
and cycling TfR and thus reduces iron uptake, it is equally 
clear that receptors with bound OKT9 continue to cycle and 
mediate  iron  uptake.  The  rate  of iron  uptake  in  antibody 
treated cells is decreased only ~20%,  a reduction consistent 
with the measured decrease in the cycling pool of TfR. More- 
over, the kinetic parameters that define the Tf cycle do not 
appear to be significantly altered by OKT9 treatment. Radio- 
labeled OKT9 was employed to show that "new" receptors 
(i.e., those that lack bound OKT9) were not responsible for 
the continued uptake of iron. The reduction in the size of the 
TfR cycling pool in OKT9-treated cells may reflect movement 
of  TfR from the pathway involved in iron uptake to a pathway 
ultimately leading to receptor degradation. Taken collectively, 
our data suggest that enhanced degradation of the TfR results 
from a relatively small decrease in recycling efficiency. 
As the TfR participates in many cycles of iron uptake in its 
lifetime,  small  decreases  in  recycling  efficiency  per  cycle 
would have profound effects on receptor half-life,  assuming 
these decreases in cycling efficiency result in a  movement of 
TfR into a pathway committed to degradation (Table II). We 
have calculated a  cycle time of 12.5 min  for Tf using the 
measured rate of iron uptake and the measured number of 
TfR in the cycling pool. If 98.2% of these receptors normally 
returned per cycle and the remaining receptors were commit- 
ted to degradation, the observed receptor half-life of 8 h would 
result. A decrease in per cycle efficiency from 98.2 to 96.5% 
would decrease the half-life by 50% to 4 h. Were the efficiency 
to drop to  86.6%  the  half-life would  fall  to  only  1 h.  The 
The Journal of Cell Biology, Volume 102, 1986  956 Table H. Effect of  Altering the Theoretical Recycling 
Efficiency on Receptor Half-life 
Theoretical recycling (efficiency per cycle)  Resultant receptor half-life 
% 
100 
99.1  16 h 
98.2  8 h 
96.5  4 h 
86.6  1 h 
50.0  12.5 min 
The above calculations are based on a first-order decay function  for the TfR. 
From the measured  rate of iron uptake and the measured  number of partici- 
pating  receptors,  a  cycle time of 12.5 min has been  calculated.  The above 
calculation of hypothetical receptor half-life assumes that receptors must leave 
the cycling pool to be degraded and that those that leave the cycling pool are 
degraded. 
shorter the  cycle time relative to  the  normal half-life of a 
receptor,  the  more  marked would  be  the  effects of rather 
subtle changes in per cycle recycling efficiency. This perspec- 
tive is based on the behavior of the entire population of TfR 
involved in iron uptake. In OKT9-treated cells, the population 
of TfR molecules appears to recycle with an efficiency only 
slightly decreased  from that  seen  in  untreated  cells.  If the 
population of TfR is heterogeneous with regard to the nature 
of OKT9 binding, or if the nature of OKT9 TfR interaction 
can change with time, then recycling of a  subpopulation of 
TfR may be more markedly affected. Nonetheless, this must 
be  manifested in  such  a  way as  to  result  in  only a  small 
decrease in the recycling probability within the TfR popula- 
tion in OKT9-treated cells. 
Perhaps the most common effect observed upon treatment 
of cells with various anti-receptor antibodies is a reduction in 
cell surface receptor number.  This has been  previously re- 
ported  for the  receptors  for insulin  (5,  23,  28),  epidermal 
growth factor (4), mannose-6-phosphate (30),  and Tf (7). We 
have observed a  similar phenomenon  regarding the  TfR in 
K562 cells treated with phorbol myristic acid or upon addition 
of human diferric Tf (10).  We have observed that neither the 
OKT9-mediated redistribution described here nor the phorbol 
myristic  acid  effect  is  additive  to  the  human  Tf-induced 
reduction in surface receptors. It is possible that the mecha- 
nism involved in all of these may be similar. We have also 
observed that incubations of cells at 37"C without a 5% CO2 
atmosphere appeared to lead to a "spontaneous" decrease in 
surface receptors, whereas surface receptor number on cells 
maintained inside an incubator remained relatively constant. 
The reason for this effect remains obscure but the observation 
demonstrates the need to carefully scrutinize even seemingly 
routine experimental manipulations. This phenomenon may 
account in part for the lack of consensus that exists regarding 
constitutive versus ligand-induced cycling of the TfR (10, 32). 
The OKT9-mediated loss of TfR from the cycling pool was 
accompanied  by  an  increase  in  J25I-Tf that  remained  cell 
associated during multiple cycles of endocytosis, i.e.,  ~25I-Tf 
that did not exchange with extracellular unlabeled ligand in 
the presence of the protease inhibitor leupeptin. This suggests 
that it is a  complex of antibody, receptor, and ligand that is 
removed from participation in iron uptake. In both control 
and  OKT9-treated  cells,  omission  of the  leupeptin  in  this 
experiment resulted in less cell-associated radioactivity in this 
nonexchanging  pool.  Degradation  of  cell-associated  12~I- 
OKT9 also exhibited sensitivity to leupeptin. Although  not 
unambiguously shown by these experiments, lysosomal deg- 
radation of ~25I-OKT9 and  125I-Tf  would be consistent with 
the leupeptin sensitivities of both OKT9 degradation and the 
OKT9-mediated ~25I-Tf  accumulation. That chloroquine also 
inhibits ~2~I-OKT9  degradation is in accord with this hypoth- 
esis. 
In the course of submission and revision of this manuscript 
Lesley and Schulte (17) published a paper that supports some 
of the results that we present here. These authors report that 
treatment of mouse lymphoma cells  with monoclonal anti- 
bodies directed against the murine TfR reduces cell surface 
expression of the TfR and enhances degradation of surface 
radioiodinated TfR. 
Ligands of the receptors for insulin and epidermal growth 
factor result in enhancement of receptor degradation (8,  12- 
14,  27).  Insulin also appears to induce  redistribution  of its 
receptor (13). Although the molecular mechanism(s) involved 
in these phenomena remain obscure, the phenomena them- 
selves resemble the effects reported here of OKT9 on the TfR 
of K562 cells.  It is unclear as to whether these observations 
using a  monoclonal antibody have a  relationship to ligand 
mediated  down-regulation.  This determination  will  require 
additional  insight  into  the  molecular signalling events that 
distinguish  the  pathways traversed by the  TfR  from those 
involved in down regulation. 
Received for publication 11 June 1985, and in revised form 1 Novem- 
ber 1985. 
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